{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:10:35Z","timestamp":1784761835507,"version":"3.55.0"},"reference-count":91,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RO1NS139383"],"award-info":[{"award-number":["RO1NS139383"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P20GM109025"],"award-info":[{"award-number":["P20GM109025"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002565","name":"Alzheimer's Drug Discovery Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002565","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","intpsychogeriatrics.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Psychogeriatrics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.inpsyc.2025.100107","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T15:51:57Z","timestamp":1750780317000},"page":"100107","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical trials for neuropsychiatric syndromes in major and mild neurocognitive disorders: A CONSORT-based approach"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8944-4158","authenticated-orcid":false,"given":"Jeffrey L.","family":"Cummings","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Sano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacobo","family":"Mintzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.inpsyc.2025.100107_bib1","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","article-title":"Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019","volume":"7","author":"GBD 2019 Dementia Forecasting Collaborators","year":"2022","journal-title":"Lancet Public Health"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100107_bib2","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/alz.12362","article-title":"Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060)","volume":"17","author":"Rajan","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100107_bib3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jalz.2017.10.009","article-title":"Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States","volume":"14","author":"Brookmeyer","year":"2018","journal-title":"Alzheimers Dement"},{"issue":"10284","key":"10.1016\/j.inpsyc.2025.100107_bib4","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100107_bib5","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1001\/jama.288.12.1475","article-title":"Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study","volume":"288","author":"Lyketsos","year":"2002","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1515\/med-2020-0124","article-title":"Neuropsychiatric symptoms, quality of life and caregivers' burden in dementia","volume":"15","author":"Majer","year":"2020","journal-title":"Open Med (Wars)"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100107_bib7","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamaneurol.2023.3810","article-title":"Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial","volume":"80","author":"Lee","year":"2023","journal-title":"JAMA Neurol"},{"issue":"9916","key":"10.1016\/j.inpsyc.2025.100107_bib8","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","author":"Cummings","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100107_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002500","article-title":"Impact of person-centred care training and person-centred activities on quality of life, agitation, and antipsychotic use in people with dementia living in nursing homes: A cluster-randomised controlled trial","volume":"15","author":"Ballard","year":"2018","journal-title":"PLoS Med"},{"issue":"5","key":"10.1016\/j.inpsyc.2025.100107_bib10","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/AOG.0b013e3181d9d421","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials","volume":"115","author":"Schulz","year":"2010","journal-title":"Obstet Gynecol"},{"issue":"22","key":"10.1016\/j.inpsyc.2025.100107_bib11","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1001\/jama.2022.21022","article-title":"Guidelines for reporting outcomes in trial reports: the CONSORT-outcomes 2022 extension","volume":"328","author":"Butcher","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.inpsyc.2025.100107_bib12","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100107_bib13","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: defining standard protocol items for clinical trials","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib14","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0749-0690(03)00046-6","article-title":"Behavioral and psychologic symptoms of dementia","volume":"19","author":"Finkel","year":"2003","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1017\/S1041610214001963","article-title":"Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition","volume":"27","author":"Cummings","year":"2015","journal-title":"Int Psychogeriatr"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100107_bib16","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jagp.2020.09.002","article-title":"Criteria for psychosis in major and mild neurocognitive disorders: International Psychogeriatric Association (IPA) consensus clinical and research definition","volume":"28","author":"Cummings","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib17","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1017\/S1041610222001041","article-title":"Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition","volume":"36","author":"Sano","year":"2024","journal-title":"Int Psychogeriatr"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100107_bib18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0749-0690(05)70073-2","article-title":"Pharmacologic therapy for behavioral symptoms of Alzheimer's disease","volume":"17","author":"Tariot","year":"2001","journal-title":"Clin Geriatr Med"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib19","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/14737175.2024.2407836","article-title":"A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease","volume":"25","author":"Zhong","year":"2025","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"10.1016\/j.inpsyc.2025.100107_bib20","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"issue":"11","key":"10.1016\/j.inpsyc.2025.100107_bib21","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1136\/jnnp-2018-317970","article-title":"Tau-induced focal neurotoxicity and network disruption related to apathy in Alzheimer's disease","volume":"89","author":"Kitamura","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.inpsyc.2025.100107_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1124145","article-title":"Validity of CSF alpha-synuclein to predict psychosis in prodromal Alzheimer's disease","volume":"14","author":"Monge-Garc\u00eda","year":"2023","journal-title":"Front Neurol"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100107_bib23","article-title":"Alzheimer's disease drug development pipeline: 2025","volume":"11","author":"Cummings","year":"2025","journal-title":"Alzheimers Dement (N Y"},{"issue":"16","key":"10.1016\/j.inpsyc.2025.100107_bib24","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","article-title":"Relapse risk after discontinuation of risperidone in Alzheimer's disease","volume":"367","author":"Devanand","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib25","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa2034634","article-title":"Trial of pimavanserin in dementia-related psychosis","volume":"385","author":"Tariot","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100107_bib26","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1002\/sim.9349","article-title":"Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison design","volume":"41","author":"Liu","year":"2022","journal-title":"Stat Med"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100107_bib27","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: A randomized clinical trial","volume":"314","author":"Cummings","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.inpsyc.2025.100107_bib28","article-title":"FOXY - a phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia","author":"Coleman","year":"2025","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib29","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13195-022-01015-6","article-title":"The role of basket trials in drug development for neurodegenerative disorders","volume":"14","author":"Cummings","year":"2022","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100107_bib30","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with Alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.7230","article-title":"Lecanemab for patients with early Alzheimer disease: Bayesian analysis of a phase 2b dose-finding randomized clinical trial","volume":"6","author":"Berry","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.inpsyc.2025.100107_bib32","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejpb.2022.06.006","article-title":"Rational and practical considerations to guide a target product profile for patient-centric drug product development with measurable patient outcomes - A proposed roadmap","volume":"177","author":"Stegemann","year":"2022","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.inpsyc.2025.100107_bib33","series-title":"Guidance for Industry. Formal Meetings between the FDA and Sponsors or Applicants of PDUFA Products","author":"Food","year":"2023"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib34","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijrobp.2021.07.1700","article-title":"An overview of phase 2 clinical trial designs","volume":"112","author":"Torres-Saavedra","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"20","key":"10.1016\/j.inpsyc.2025.100107_bib35","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1212\/WNL.0000000000011774","article-title":"Value-generating exploratory trials in neurodegenerative dementias","volume":"96","author":"Friedman","year":"2021","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib36","first-page":"10","article-title":"Phase III design: principles","volume":"5","author":"Buyse","year":"2016","journal-title":"Chin Clin Oncol"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100107_bib37","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1017\/S1041610215001106","article-title":"Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial","volume":"27","author":"Rosenberg","year":"2015","journal-title":"Int Psychogeriatr"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","article-title":"New approaches to symptomatic treatments for Alzheimer's disease","volume":"16","author":"Cummings","year":"2021","journal-title":"Mol Neurodegener"},{"issue":"9","key":"10.1016\/j.inpsyc.2025.100107_bib39","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/JGP.0b013e3181b0f8c0","article-title":"Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial)","volume":"17","author":"Ballard","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.inpsyc.2025.100107_sbref40","series-title":"Programme grants for applied research. Improving mental health and reducing antipsychotic use in people with dementia in care homes: the WHELD research programme including two RCTs","author":"Ballard","year":"2020"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2174\/1567205043332027","article-title":"Regression to the mean: implications for clinical trials of psychotropic agents in dementia","volume":"1","author":"Cummings","year":"2004","journal-title":"Curr Alzheimer Res"},{"issue":"7","key":"10.1016\/j.inpsyc.2025.100107_bib42","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2174\/156720510793499057","article-title":"Inaccuracy in clinical trials: effects and methods to control inaccuracy","volume":"7","author":"Kobak","year":"2010","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100107_bib43","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s43441-022-00496-9","article-title":"Risk-based monitoring in clinical trials: 2021 update","volume":"57","author":"Adams","year":"2023","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.inpsyc.2025.100107_bib44","series-title":"Diagnostic and Statistical Manual of Mental Disorders, Text Revision Dsm-5-tr","author":"American Medical Association","year":"2022"},{"key":"10.1016\/j.inpsyc.2025.100107_bib45","series-title":"ICD-10-CM 2025 the Complete Official Codebook (ICD-10-CM the Complete Official Codebook)","author":"American Medical Association","year":"2024"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100107_bib46","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100107_bib47","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/brain\/awab365","article-title":"Proposed research criteria for prodromal behavioural variant frontotemporal dementia","volume":"145","author":"Barker","year":"2022","journal-title":"Brain"},{"issue":"17","key":"10.1016\/j.inpsyc.2025.100107_bib48","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","article-title":"Research criteria for the diagnosis of prodromal dementia with Lewy bodies","volume":"94","author":"McKeith","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.inpsyc.2025.100107_bib49","series-title":"Early Alzheimer\u2019s Disease: Developing Drugs for Treatment. Guidance for Industry","author":"Food and Drug Administration","year":"2024"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100107_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/alz.70038","article-title":"Diagnostic accuracy of plasma p-tau217\/Abeta42 for Alzheimer's disease in clinical and community cohorts","volume":"21","author":"Wang","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"8","key":"10.1016\/j.inpsyc.2025.100107_bib51","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100107_bib52","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/brain\/awaa438","article-title":"The development and convergence of co-pathologies in Alzheimer's disease","volume":"144","author":"Robinson","year":"2021","journal-title":"Brain"},{"issue":"7","key":"10.1016\/j.inpsyc.2025.100107_bib53","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/WAD.0000000000000144","article-title":"Amyloid PET screening for enrichment of early-stage Alzheimer disease clinical trials: experience in a phase 1b clinical trial","volume":"30","author":"Sevigny","year":"2016","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib55","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41398-022-01850-z","article-title":"Increased retention of tau PET ligand [(18)F]-AV1451 in Alzheimer's Disease Psychosis","volume":"12","author":"Gomar","year":"2022","journal-title":"Transl Psychiatry"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100107_bib56","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/JGP.0b013e3181c796eb","article-title":"Sertraline for the treatment of depression in Alzheimer disease","volume":"18","author":"Rosenberg","year":"2010","journal-title":"Am J Geriatr Psychiatry"},{"issue":"16","key":"10.1016\/j.inpsyc.2025.100107_bib57","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1212\/WNL.0b013e3182516244","article-title":"A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease","volume":"78","author":"Richard","year":"2012","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib58","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1176\/appi.neuropsych.21060166","article-title":"Advances in treatment of frontotemporal dementia","volume":"34","author":"Magrath Guimet","year":"2022","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib59","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41596-022-00787-3","article-title":"Seed amplification assay for the detection of pathologic alpha-synuclein aggregates in cerebrospinal fluid","volume":"18","author":"Concha-Marambio","year":"2023","journal-title":"Nat Protoc"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100107_bib60","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/s41591-024-02937-4","article-title":"Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS","volume":"30","author":"Chatterjee","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100107_bib61","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/alz.12358","article-title":"Diagnostic criteria for apathy in neurocognitive disorders","volume":"17","author":"Miller","year":"2021","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100107_bib62","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/00019442-200203000-00003","article-title":"Provisional diagnostic criteria for depression of Alzheimer disease","volume":"10","author":"Olin","year":"2002","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100107_bib63","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1001\/jamaneurol.2024.0586","article-title":"Progress in pharmacologic management of neuropsychiatric syndromes in neurodegenerative disorders: a review","volume":"81","author":"Cummings","year":"2024","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100107_bib64","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1097\/00002093-199700112-00007","article-title":"Assessing patterns of agitation in Alzheimer's disease patients with the Cohen-Mansfield Agitation Inventory","volume":"11","author":"Koss","year":"1997","journal-title":"Alzheimer'S Dis Coop Study Alzheimer Dis Assoc Disord"},{"issue":"12","key":"10.1016\/j.inpsyc.2025.100107_bib65","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","article-title":"The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia","volume":"44","author":"Cummings","year":"1994","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib66","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-023-01355-x","article-title":"A multimodal precision-prevention approach combining lifestyle intervention with metformin repurposing to prevent cognitive impairment and disability: the MET-FINGER randomised controlled trial protocol","volume":"16","author":"Barbera","year":"2024","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.inpsyc.2025.100107_bib67","article-title":"An adaptive method for assigning clinical trials wait-times for controls","volume":"21","author":"Sima","year":"2021","journal-title":"Conte Clin Trials Commun"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100107_bib68","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.biopsych.2023.12.004","article-title":"Accelerated theta burst stimulation: safety, efficacy, and future advancements","volume":"95","author":"Cole","year":"2024","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.inpsyc.2025.100107_bib69","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3233\/JAD-160979","article-title":"The Mild Behavioral Impairment Checklist (MBI-C): A rating scale for neuropsychiatric symptoms in pre-dementia populations","volume":"56","author":"Ismail","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib70","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"Am J Geriatr Psychiatry"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100107_bib71","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1017\/S1041610210000876","article-title":"The Neuropsychiatric Inventory-Clinician rating scale (NPI-C): reliability and validity of a revised assessment of neuropsychiatric symptoms in dementia","volume":"22","author":"de Medeiros","year":"2010","journal-title":"Int Psychogeriatr"},{"key":"10.1016\/j.inpsyc.2025.100107_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2021.105250","article-title":"Blood-based biomarkers of agitation in Alzheimer's disease: Advances and future prospects","volume":"152","author":"Tumati","year":"2022","journal-title":"Neurochem Int"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100107_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/cells11061030","article-title":"Cerebrospinal fluid proteome alterations associated with neuropsychiatric symptoms in cognitive decline and Alzheimer's disease","volume":"11","author":"Mroczek","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.inpsyc.2025.100107_bib74","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.809071","article-title":"Proteomic analysis of plasma markers in patients maintained on antipsychotics: comparison to patients off antipsychotics and normal controls","volume":"13","author":"Engelke","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.inpsyc.2025.100107_bib75","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/978-981-97-4402-2_18","article-title":"Precision medicine in depression: the role of proteomics and metabolomics in personalized treatment approaches","volume":"1456","author":"Jaber","year":"2024","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib76","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s43441-022-00402-3","article-title":"Marking 2-years of new thinking in clinical trials: the estimand journey","volume":"56","author":"Fletcher","year":"2022","journal-title":"Ther Innov Regul Sci"},{"issue":"Pt A","key":"10.1016\/j.inpsyc.2025.100107_bib77","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cct.2015.05.018","article-title":"Design of clinical trials with failure-time endpoints and interim analyses: An update after fifteen years","volume":"45","author":"He","year":"2015","journal-title":"Conte Clin Trials"},{"issue":"6","key":"10.1016\/j.inpsyc.2025.100107_bib78","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.5811\/westjem.2017.8.35985","article-title":"Understanding the Intention-to-treat Principle in Randomized Controlled Trials","volume":"18","author":"McCoy","year":"2017","journal-title":"West J Emerg Med"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib79","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.2013.285063","article-title":"How to use a subgroup analysis: users' guide to the medical literature","volume":"311","author":"Sun","year":"2014","journal-title":"Jama"},{"issue":"32","key":"10.1016\/j.inpsyc.2025.100107_bib80","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"CMAJ"},{"key":"10.1016\/j.inpsyc.2025.100107_bib81","series-title":"The fundamentals of clinical research: a universal guide for implementing good clinical practice","first-page":"285","article-title":"Safety monitoring and reporting","author":"Henry","year":"2022"},{"issue":"2","key":"10.1016\/j.inpsyc.2025.100107_bib82","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3233\/JAD-231283","article-title":"Alzheimer's Disease Cooperative, S. Study partner type and adverse event reporting in mild-to-moderate Alzheimer's disease clinical trials","volume":"98","author":"Lu","year":"2024","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib83","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/19466315.2021.2000487","article-title":"Predicting the COVID-19 pandemic impact on clinical trial recruitment","volume":"14","author":"Best","year":"2022","journal-title":"Stat Biopharm Res"},{"issue":"8","key":"10.1016\/j.inpsyc.2025.100107_bib84","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1002\/alz.12293","article-title":"Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC","volume":"17","author":"Gianattasio","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.inpsyc.2025.100107_bib85","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13195-016-0201-2","article-title":"Older patients are still under-represented in clinical trials of Alzheimer's disease","volume":"8","author":"Banzi","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.1016\/j.inpsyc.2025.100107_bib86","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/alz.12433","article-title":"Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria","volume":"18","author":"Franzen","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"16","key":"10.1016\/j.inpsyc.2025.100107_bib87","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1001\/jama.2019.3087","article-title":"Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement","volume":"321","author":"Juszczak","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.inpsyc.2025.100107_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e5661","article-title":"Consort 2010 statement: extension to cluster randomised trials","volume":"345","author":"Campbell","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.inpsyc.2025.100107_bib89","doi-asserted-by":"crossref","first-page":"i5239","DOI":"10.1136\/bmj.i5239","article-title":"CONSORT 2010 statement: extension to randomised pilot and feasibility trials","volume":"355","author":"Eldridge","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.inpsyc.2025.100107_bib90","doi-asserted-by":"crossref","first-page":"a2390","DOI":"10.1136\/bmj.a2390","article-title":"Improving the reporting of pragmatic trials: an extension of the CONSORT statement","volume":"337","author":"Zwarenstein","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.inpsyc.2025.100107_bib91","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1186\/s13063-020-04334-x","article-title":"The adaptive designs CONSORT extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design","volume":"21","author":"Dimairo","year":"2020","journal-title":"Trials"}],"container-title":["International Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104161022500345X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104161022500345X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T08:31:19Z","timestamp":1779006679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104161022500345X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":91,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S104161022500345X"],"URL":"https:\/\/doi.org\/10.1016\/j.inpsyc.2025.100107","relation":{},"ISSN":["1041-6102"],"issn-type":[{"value":"1041-6102","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical trials for neuropsychiatric syndromes in major and mild neurocognitive disorders: A CONSORT-based approach","name":"articletitle","label":"Article Title"},{"value":"International Psychogeriatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.inpsyc.2025.100107","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Psychogeriatric Association.","name":"copyright","label":"Copyright"}],"article-number":"100107"}}